Heart disease is associated with re-expression of key transcription factors normally active only during prenatal development of the heart. However, the impact of this reactivation on the genome-wide regulatory landscape in heart disease has remained obscure. Here we show that pervasive epigenomic changes occur in heart disease, with thousands of regulatory sequences reacquiring fetal-like chromatin signatures. We used RNA-seq and ChIP-seq targeting a histone modification associated with active transcriptional enhancers to generate genomewide enhancer maps from left ventricle tissue from 18 healthy controls and 18 individuals with idiopathic dilated cardiomyopathy (DCM). Healthy individuals had a highly reproducible epigenomic landscape, consisting of more than 31,000 predicted heart enhancers. In contrast, we observed reproducible diseaseassociated gains or losses of activity at more than 7,500 predicted heart enhancers. Next, we profiled human fetal heart tissue by ChIP-seq and RNA-seq. Comparison with adult tissues revealed that the heart disease epigenome and transcriptome both shift toward a fetal-like state, with 3,400 individual enhancers sharing fetal regulatory properties. Our results demonstrate widespread epigenomic changes in DCM, and we provide a comprehensive data resource (http://heart.lbl.gov) for the mechanistic exploration of heart disease etiology. Correspondence: avisel@lbl.gov (A.V., lead contact), lapennacchio@lbl.gov (L.A.P.), dedickel@lbl.gov (D.E.D.)
Introduction
Heart failure resulting from cardiomyopathy is a prevailing cause of adult mortality worldwide 1 . Among cardiomyopathies, dilated cardiomyopathy (DCM) is the most common 2 and is characterized by the dilation and weakening of the left ventricle and decreased ejection fraction in the absence of coronary artery disease or other abnormalities 3 . Approximately one third of DCM cases are explained by coding mutations in known genes 4, 5 . Gene expression studies have been widely used to facilitate the identification of additional causal genetic variation and to understand the transcriptional pathways impacted during heart failure, which may provide new therapeutic targets [6] [7] [8] . Transcriptional profiling of failing hearts, including those with idiopathic DCM, has identified numerous coding and non-coding genes whose expression is altered in heart disease 7, [9] [10] [11] [12] . These studies have con-sistently shown that heart failure is associated with the reactivation of a fetal gene program: a curated set of genes with well-established roles in fetal heart development that are normally repressed in non-failing adult heart 13, 14 . Notably, a fetalization mechanism has also been suggested for similar pathways involved in lung disease 15, 16 and tumorigenesis 17 . However, the full quantitative extent of fetal gene program reactivation in disease processes and the identity of the gene regulatory sequences correlated with these changes remain unknown. Gene expression is controlled in part by enhancers, a major class of cis-regulatory elements, which can act over large genomic distances to activate gene transcription in specific cell types or developmental stages 9 . Chromatin immunoprecipitation followed by sequencing (ChIP-seq) targeting enhancer-associated chromatin marks (e.g., H3K27ac) can be used to generate accurate genome-wide maps of enhancers active in a tissue of interest 10, 18 . However, the small number of ChIP-seq data sets from individual human heart samples described to date has been insufficient to systematically assess the reproducibility of the cardiac enhancer landscape in healthy individuals or to quantify and characterize possible changes associated with disease states [19] [20] [21] . In particular, a recent study examined cardiomyocyte cells isolated from a small number of failing and non-failing hearts to explore the regulatory landscape of these cells in disease 22 but identified a very limited set of enhancers that were differentially active between these states. We performed a comprehensive exploration of human heart enhancers in left ventricle samples from an extensive cohort of control adults and individuals with dilated cardiomyopathy (see study overview in Figure 1 ). In healthy hearts, we observe a highly reproducible enhancer landscape across individuals. Furthermore, we observe major changes in the regulatory landscape of DCM samples and, through comparison with fetal heart tissue samples, demonstrate that more than 3,400 enhancers adopt fetal-like regulatory activity states in DCM. We also show that these enhancers are enriched in a specific subset of basic helix-loop-helix (bHLH) transcription factor binding sites and are sufficient to drive cardiac expression in vivo in transgenic mouse reporter assays. Fig. 1 . Overview of this study. We performed RNA-seq and ChIP-seq on left ventricle samples from 18 healthy donors. We identify reproducible enhancer predictions and gene expression patterns in healthy heart (top). Next, we identify global alterations in enhancer occupancy from 18 hearts with idiopathic dilated cardiomyopathy (DCM) (center). Last, we compare adult healthy and disease states with 5 embryonic or fetal heart and identify similarities in the enhancer landscapes of DCM and fetal heart (bottom).
P R E P R I N T
We demonstrate, through correlation with transcriptome data, that enhancers activated in disease are in close proximity to genes with increased expression in disease. Finally, we identify more than 200 fetal heart genes that are up-regulated in adult heart failure. Taken together, our findings indicate that a large number of fetal heart enhancers become consistently reactivated in heart disease, and our results identify the genomic locations and activation states of these enhancers, providing a rich resource for the exploration of mechanistic links between enhancers and clinical cardiac phenotypes.
Results
Highly Reproducible Heart Enhancer Landscape in Healthy Individuals. To assess the heterogeneity of the gene regulatory landscape in healthy human hearts, we used chromatin profiling to identify putative enhancer regions. We performed ChIP-seq with an antibody to H3K27ac on left ventricle samples from 10 male and 8 female healthy adult donor hearts for which an acceptable transplant recipient could not be found (Figure 1 , Supplementary Table 1 ). In parallel, we performed RNA-seq on these samples to enable a comparison of each enhancer profile with its associated transcrip-tome. We defined enhancers as genomic regions with significant H3K27ac enrichment that are at least 1 kbp away from the nearest transcription start site (see Methods). All chromatin and RNA-seq data from these samples, as well as disease samples described below, are available for download and browsing in an accompanying web resource (heart.lbl.gov). Control samples had an average of 17,352 putative distal enhancers, with 40% of peaks identified in any given control sample present in all other control samples, 78% shared across two-thirds of all control samples, and only 9% (685) unique to the individual (Figure 2a ). Across all 18 control samples, we identified a total of 43,363 predicted distal enhancers present in at least one sample, with more than 70% (31, 033) found in at least two individuals ( Supplementary  Figure 1 , Supplementary Table 2 ). To determine the functions of genes associated with the cardiac enhancers predicted through this approach, we examined the enrichment of functional ontology terms 24 among genes located near candidate regions showing strong H3K27ac enrichment in at least 16 healthy controls (see Methods). Among the most significantly enriched annotations derived from mouse gene expression studies, 11 of the top 20 are cardiovascular-related functions (Supplementary Table 3 ). Our results indicate that the enhancer landscape in healthy human hearts is overall highly reproducible, with quantitatively modest differences between individuals.
To verify that enhancers predicted by this ChIP-seq approach are bona fide cardiac-specific regulatory sequences, we first compared our predicted human heart enhancers with the VISTA Enhancer Browser (enhancer.lbl.gov), an existing catalog of in vivo validated enhancers 23 . This database contains 283 human and mouse loci that have been tested using transgenic mouse assays and have validated activity in the heart. Nearly 55% (n=154) of these validated heart enhancers overlapped peaks in our adult human heart samples (Supplementary Table 2 ). We additionally performed forward in vivo validation using transgenic mouse reporter assays 25 at embryonic day 11.5 for several candidate human adult heart enhancers. Examples of reproducible in vivo cardiac reporter activity driven by different candidate enhancers, including one near PDLIM3, are shown in Figure 2b , c. Together, these results reinforce that predicted adult heart enhancers drive gene expression in heart tissue.
Genome-wide Changes in Enhancer Architecture in DCM.
We next evaluated possible global changes in enhancer architecture in heart disease using transcriptome and chromatin profiling on explanted left ventricle samples from individuals with late stage idiopathic DCM. ChIP-seq data were generated from 18 DCM cases that were age-and sexmatched to the 18 healthy control samples (see Methods, Supplementary Table 1 ), and we obtained RNA-seq data from 15 of the 18 DCM left ventricle samples. Across the two sets of samples (healthy and DCM), the greatest driver of variance is disease state, explaining 18.1% of the variability in gene expression and 18.3% of the variability in predicted enhancers (Figure 3a Figure 2 for results for additional predicted heart enhancers). One representative embryonic day 11.5 embryo is shown for each enhancer, and numbers in red show the reproducibility of heart staining in each transgenic experiment. Information underneath each embryo includes the identification number in the VISTA Enhancer Browser 23 (enhancer.lbl.gov) and the human genome coordinates (hg38) of each tested enhancer. Figure 3 ). Of the 18,913 genes expressed in at least two individuals, 870 (4.6%) were differentially expressed between disease and health, with 416 upregulated in DCM and 454 downregulated in DCM (P < 0.01, |log 2 (fold change)| ≥ 1; Figure 3c , Supplementary Table  4 ). From the combined pool of 36 left ventricle H3K27ac ChIP-seq samples, we identified 38,883 predicted enhancers present in at least two individuals ( Supplementary Table 5 ). Our large sample size provided sufficient power to use differential peak analysis 26 to identify enhancers with quantitative differences between healthy and DCM samples that could be contributing to or resulting from the observed gene expression differences. We identified 7,507 (19%) enhancers that are differentially bound between healthy and DCM samples (P < 0.01 and |log 2 (fold change)| ≥ 1; DiffBind DESeq analysis, see Methods and Supplementary Table 6 ). Among these differential peaks, 4,406 show increased signal in DCM relative to healthy controls, whereas 3,101 have increased predicted enhancer activity in controls (Figure 3c , Supplementary Table 6 ). These results show that, in addition to the dysregulation of hundreds of cardiac-expressed genes, the genome-wide enhancer architecture is substantially altered in left ventricle from DCM patients.
samples (Supplementary
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Pathways. To further assess the regulatory relationship between differentially active enhancers and differentially expressed genes in DCM, we examined correlations between RNA-seq and ChIP-seq data. We observed multiple anecdotal examples of differentially active enhancers located near genes with the same directionality of differential expression. An illustrative example is provided by the SMOC2 locus, where a strong, DCM-specific increase in H3K27ac signal at a site 20 kb upstream of the promoter correlates with a strong increase in SMOC2 expression in DCM (Figure 4a the most pronounced enrichment observed within the 100 kb window closest to the promoter (Figure 4b , c). To assess the biological functions of the differentially expressed genes and differentially active enhancers, we examined their enrichment for biological process ontology terms 24 . For the 4,406 enhancer peaks with predicted increased activity in DCM, there is enrichment for terms including extracellular matrix remodeling ( Supplementary  Table 7 ). Similarly, genes up-regulated in DCM independently show enrichment for extracellular matrix components and cell adhesion ( Supplementary Table 8 ). These results reinforce our conclusion that DCM-specific enhancers are enriched near genes that are differentially regulated in disease, highlighting fibrosis pathways in heart failure 27 . To identify candidate transcription factors (TFs) that may be driving altered enhancer activity in DCM, we performed binding site enrichment analysis 28 for distal enhancer peaks with increased or decreased activity in DCM. In peaks with increased activity in DCM, binding sites for bHLH transcription factors are enriched ( Figure 4d) . Several of the most sig-nificant factors in this class, including TCF4 and TCF21, are involved in epithelial-to-mesenchymal transition 29 , which may contribute to cardiac fibrosis 30 . In peaks with decreased activity in DCM, there is enrichment in nuclear receptor transcription factor binding sites ( Figure 4e ). We found particularly pronounced enrichment in glucocorticoid response elements (GRE), which are involved in growth and immune response pathways 31 . We also found enrichment of bZIP factors that are part of the AP-1 complex, which has been suggested to act as homeostatic regulator required to maintain a steady state of cell proliferation 32, 33 . Taken together, these data show that heart disease-associated enhancers are enriched near genes differentially regulated in disease and that known functions of these genes are consistent with roles in heart failure.
Fetalization of the Regulatory Landscape in Heart Disease.
Previous studies have reported that some genes that are essential for fetal heart development are downregulated in adult heart, but become reactivated in failing hearts 7, 13, 34 . However, beyond anecdotal examples, the transcriptomewide scale of such re-expression of prenatally expressed human genes in DCM has remained unclear. Likewise, it is unknown whether reactivation of these fetal genes is associated with reactivation of fetal regulatory elements. To comprehensively define the fetal gene program reactivated in dilated cardiomyopathy and to test whether enhancer regulation correlates with the re-expression of fetal genes, we performed ChIP-seq and RNA-seq on five embryonic and fetal human heart samples, covering developmental stages ranging from 8 weeks to 17 weeks post conception (Figure 5a , Supplementary Tables 9, 10 ; see Methods for sample details). We performed principal component analysis followed by dimensionality reduction using t-SNE to capture variation from multiple principal components for healthy, DCM, and prenatal samples (Figure 5b, c; Supplementary Figure 4 ; and Methods). These analyses, capturing the local and global structure of complex data for visualization in two dimensions 35 , indicate that the three groups of samples (adult controls, adult DCM, fetal) show distinct genome-wide transcriptome and enhancer signatures (Figure 5b, c) . Consistent with the notion of reactivation of fetal genes in heart disease, we found that genes expressed during fetal development are enriched among those upregulated in DCM relative to healthy adult heart and vice versa ( Supplementary Figure 4c, d) .
In total, of the 416 genes upregulated in DCM, 213 are upregulated in fetal heart relative to healthy adult. To examine if this coincides with enhancers returning to a fetal-like state in heart disease, we focused on the activity states of 4,547 regions that showed differential H3K27ac binding in both health versus DCM, as well as in adult versus fetal samples. The majority of these enhancers (76%, n=3,471) show the same activity state in fetal and adult DCM heart, respectively, resulting in an overlap of DCM-and fetal-biased peaks that was enriched 1.6-fold relative to the overlap expected by chance (Figure 5d, e ). For the 1,622 enhancers with predicted increased activity in DCM and fetal, there is enrichment for gene ontology terms associated with fibrosis and extracellular matrix remodeling, along with terms involving TGFβ signaling ( Supplementary Table 11 ). Genes in these pathways are upregulated in cardiac development and in heart failure 36, 37 . In addition to enhancers that showed fetal-like regulatory properties in DCM, we also observed populations of enhancers that are either anti-correlated with fetal enhancer activity states (n=1,076) or that were DCM-specific, i.e. showed activity states that were different from fetal and healthy adult cardiac tissue (n=2,960). Both of these groups of enhancers indicate that while the genome-wide alterations in enhancer landscape in DCM are dominated by a shift toward fetal-like signatures, there are clearly additional, DCMspecific molecular events, as expected from the pathological context associated with heart disease. To provide addi-tional insight into gene regulatory processes that are shared between DCM and fetal development versus those that are specific to DCM, we examined enrichment of transcription factor binding site motifs in the 1,622 enhancers that have increased activity in both versus the 2,784 that are upregulated only in DCM. Both sets of enhancers were generally enriched for bHLH transcription factor binding motifs, but we observed the most significant enrichment for distinct subsets of bHLH motifs (Supplementary Figure 5) . For example, enhancers with increased activity in both DCM and fetal samples were especially enriched in motifs for MyoD and Myf5, proteins with well-established roles in myogenesis 38 . Taken together, our results support that the upregulation of fetal genes in DCM is accomplished through the reactivation of fetal enhancers. Importantly, the genome-wide expression P R E P R I N T and enhancer maps generated through this study will enable the targeted follow-up of regulatory events associated with the pervasive reactivation of fetal expression programs, as well as molecular downstream events specifically associated with disease progression.
Discussion
Understanding the mechanisms regulating gene expression in healthy and pathological states of the heart is critical for understanding cardiac biology and disease. By performing enhancer discovery by ChIP-seq on heart tissues from a sizable cohort of individuals, we were able to assess the baseline variation in heart enhancer landscape across the population. Importantly, we found that the activity of cardiac enhancers is well conserved across individuals. This observation, together with the underlying comprehensive maps of heart enhancers generated through this study, provides an important reference point for assessing the impact of environmental factors, genetic variation, and disease-associated molecular processes on cardiac gene regulation. Similar to the high reproducibility of the enhancer landscape in the healthy heart, our systematic assessment of enhancers in DCM, the most common cardiomyopathy, revealed disease-associated activity changes in thousands of enhancers that were highly reproducible across individuals. This insight implies that pathological disease states of the heart are not associated with a general disruption of coordinated gene expression, but instead show a complex, but well-defined shift in genome-wide transcriptional regulation involving a distinct set of distant-acting enhancers. Finally, our comparison with data from fetal heart tissue uncovered that, beyond the limited number of examples described to date 13, 14 , hundreds of fetal genes and more than a thousand fetal enhancers become consistently reactivated in adult heart disease. Our study identified the genomic locations and activation states of this intriguing subset of diseaseassociated enhancers, offering an entry point for targeted experimental exploration for hundreds of genes with diseaseassociated activity changes. Reactivation of individual fetal pathways has also been observed in other, non-cardiac disease processes [15] [16] [17] . While limited to anecdotal examples, in conjunction with data from the present study, these reports raise the possibility that widespread reactivation of fetal enhancers is a more generalized disease-associated phenomenon. Taken together, our study highlights how the etiology of a disease process with major epidemiological relevance is tightly interlinked with, and possibly driven by, reproducible activity changes across thousands of enhancers in the human genome. The identification of substantial overlap between diseaseassociated and developmentally active cardiac enhancers reinforces the notion that modulation of genes and pathways normally active in the embryonic and fetal heart may impact on disease progression 13 , thus providing inspiration for new therapeutic strategies.
Methods
Contact for Reagent and Resource Sharing. All plasmids and reagents generated in this study, as well as archived surplus LacZ-stained embryos for selected enhancers are available from the authors. Please contact Axel Visel (avisel@lbl.gov). Transgenic mouse assays. All animal work was reviewed and approved by the Lawrence Berkeley National Laboratory Animal Welfare and Research Committee. Transgenic assays were performed in Mus musculus FVB strain mice and included both male and female embryos. Sample sizes were selected based on our previous experience of performing transgenic mouse assays for >2,000 enhancer candidates 23, 39 . Mouse embryos were only excluded from further analysis if they did not carry the reporter transgene or if they were not at the correct developmental stage. Randomization and experimenter blinding were unnecessary and not performed for transgenic assays, as all resulting embryos were treated with identical experimental conditions and no direct comparisons were made between groups of mice.
Human
ChIP-seq. Chromatin immuno-precipitations were performed as previously described 40 with some modifications. Briefly, frozen left ventricle tissue was pulverized with a mortar and pestle, resuspended in PBS, and cross-linked with 1% formaldehyde at room temperature for 10 min. Chromatin was sonicated to obtain fragments with an average size ranging between 100-600 bp. Chromatin was incubated P R E P R I N T for 2h at 4°C with 5 µg of Active Motif H3K27ac antibody (cat#39133, lot 01613007). Protein A and G Dynabeads (Invitrogen) were then added to this chromatin/antibody mixture for 30 minutes at 4°C. Immuno-complexes were sequentially washed. The protein/DNA complexes were eluted in an SDS buffer (1% SDS, 50 mM Tris pH 8.0, 10 mM EDTA) at 37°C for one hour. Samples were treated with Proteinase K at 37°C and reverse-crosslinked overnight. Finally, the DNA was purified on Zymo ChIP clean and concentrate columns (Zymo Research), and the quality was assessed on the Agilent bioanalyzer. The ChIP-seq libraries were prepared using the Illumina TruSeq library preparation kit followed by pooling of libraries. Libraries were pooled and sequenced via single end 50 bp reads on a HiSeq 2500 (6 libraries per lane) or HiSeq 4000 (8 libraries per lane)(Illumina). ChIP-seq data was analyzed using the ENCODE Uniform Processing Pipelines (https://www.encodeproject.org/pipelines/) implemented at DNAnexus (https://www.dnanexus.com). ChIP-seq data was analyzed using the ENCODE histone ChIP-seq Unary Control Unreplicated (GRCh38) -pipeline version 1.2 (code available from https://github.com/ENCODE-DCC/chipseq-pipeline). Briefly, reads were mapped to the human genome (GRCh38) using bwa aln v 0.7.10 41 with settings -q 5 -l 32 -k 2. Duplicate reads were identified and removed using PICARD (https://broadinstitute.github.io/picard/). Non-duplicate reads were used as input for peak calling using MACS 2.0 42 , with the experiment-matched input DNA used as a control. The average enhancer peak was 6,526 bp long.
RNA-seq. RNA was isolated from homogenized left ventricle using the TRIzol Reagent (Life Technologies). RNA samples were DNase-treated with the TURBO DNA-free Kit (Life Technologies), and RNA quality was then assessed using a 2100 Bioanalyzer (Agilent) with an RNA 6,000 Nano Kit (Agilent). RNA sequencing libraries were made using the TruSeq Stranded Total RNA with Ribo-Zero Human/Mouse/Rat kit (Illumina) according to manufacturer instructions. RNA-seq libraries were subjected to an additional purification to remove remaining high molecular weight products as follows: sample volume was increased to 100 µl by addition of 1X TE buffer or Illumina Resuspension Buffer and then incubated with 60 µl Agencourt AM-Pure XP beads for 4 min. The beads were pelleted by incubation on a magnet, and the entire supernatant was transferred to a tube containing 50 µl of fresh AMPure XP beads and incubated for 4 min. After pelleting the new beads with a magnet, the supernatant was discarded, the beads washed twice with 80% ethanol and the DNA was eluted in 30 µl Illumina Resuspension buffer. The resulting RNAseq libraries were diluted 10×, and their quality and concentration were assessed using a 2100 Bioanalyzer with the High Sensitivity DNA Kit (Agilent) and a Qubit Fluorometer with the Qubit dsDNA HS Assay Kit (Life Technologies). RNAseq libraries were pooled and sequenced via single end 50 bp reads on a HiSeq 2500 (4 libraries per lane) or HiSeq 4000 (6 libraries per lane)(Illumina). Like ChIP-seq, RNA-seq data was analyzed using the DNAnexus instance of the ENCODE Uniform Processing Pipeline. RNA-seq data was analyzed using the ENCODE RNA-Seq (Long) Pipeline -1 (single-end) replicate pipeline (code available from https://github.com/ENCODE-DCC/rnaseq-pipeline). Briefly, reads were mapped to the human genome (GRCh38) using STAR align (V2.12). Genomewide coverage plots were generated using bam to signals (v2.2.1). Gene expression counts were generated for gencode v24 gene annotations using RSEM (v1.4.1). Differential binding analysis. Differential peak analysis between two phenotypes (healthy adult vs DCM adult left ventricle; healthy adult left ventricle vs fetal heart) was performed using DiffBind 26 version 2.10.0. We identified all autosomal differential peaks at least 1,000 bp from a transcription start site using Gencode 43 version 27 annotations. Peaks present in at least two individuals were defined using the dba.count function in DiffBind, and these peaks were used to generate a list of consensus peaks for comparison with downstream differential analysis. We used the DBA_DESEQ2 method to call differential peaks using the multiple testing corrected FDR ≤ 0.05. Final differentially bound datasets were further filtered to have a two-sided P value < 0.01 and |log 2 (fold change)| ≥ 1. To reduce the dimensionality of the dataset and visualize the samples in two dimensions, the master dataset generated by DiffBind (namely the normalized signal quantifications in all the regions tested across all samples) were log-2 transformed and scaled (zscore by region), and then subject to Principal Component Analysis (PCA) using the prcomp package in R. t-SNE 35 was run using Seurat 44 version 2.3.4. TMM-normalized counts were log2-converted, imported in a Seurat object, and scaled. PCA was then run using regions showing highly variable signal (mean.function = ExpMean, dispersion.function = LogVMR, x.low.cutoff = 0, x.high.cutoff = 14, y.cutoff = 1, num.bin=100). To determine the correct settings for t-SNE visualization, the optimal number of components was determined by JackStraw, resulting in the top 4 components to be used as input for the t-SNE. This was run using the Seurat internal function and perplexity set to values in the following range: [2, 4, 6, 8, 10, 12] . Figures show t-SNE graphs with perplexity of 10. 45 version 3.20.9. First, genes whose expression was extremely low in most samples were discarded from further analyses (only those genes showing counts per million mapped reads (CPM) ≥ 1 in three or more samples were retained for further analyses). Next, estimateCommonDisp and estimateTagwiseDisp (prior.df = 10) were run to properly handle over-dispersion at the global and single gene level. Across samples, normalization was then performed using TMM, via the function calcNormFactors. Differentially expressed genes were deter-P R E P R I N T mined using the exactTest function, as those showing a false discovery rate (FDR) (Benjamini-Hochberg correction) < 5% and a linear fold-change of at least 2, in either direction. The total number of expressed genes includes all genes present in at least two samples with normalized CPM (counts per million) of at least 1. PCA was performed as described in the previous paragraph, using the log2-transformed, TMMnormalized expression values as input. PCA results were robust to the choice of the most variable genes used as input (range tested: 1,000 to 10,000). t-SNE 35 was run using Seurat 44 as described in the previous paragraph, with the exception of the parameters used to identify highly variable signal (mean.function = ExpMean, dispersion.function = LogVMR, x.low.cutoff = 0, x.high.cutoff = 20, y.cutoff = 1, num.bin=100). The optimal number of PCs for t-SNE was determined to be 5 (by JackStraw).
Differential gene expression. Differential gene expression analysis (autosomal genes only) between two phenotypes (healthy adult vs DCM adult left ventricle; healthy adult left ventricle vs fetal heart) was performed using edgeR
Gene enrichment.
To identify gene ontologies enriched in differential regions we ran GREAT 24 version 3.0.0 using default settings, including the association rule: Basal+extension: 5,000 bp upstream, 1,000 bp downstream, 1,000,000 bp max extension, curated regulatory domains included. We used the Lift Genome Annotations tool in the UCSC genome browser (genome.ucsc.edu) to convert hg38 regions to hg19 regions required for GREAT input. We identified the most significant terms by binomial q value using the GO Biological Process and GO Molecular Function ontologies. To identify gene ontologies represented in differentially expressed genes, we used PANTHER 46 version 10.0 and ran the PANTHER Overrepresentation Test (release 20181113).
Transcription factor binding site analysis. We ran HOMER 28 v. 4.10.3 using findMotifsGenome.pl with the following parameters: -size -500,500 -len 6,7,8,9,10,12,14. We used a hypergeometic distribution to estimate the P value of the enrichments. Input regions were split into 1-kbp bins prior to analysis.
Closest transcription factor start site comparison. We calculated the nearest transcription start site upregulated in DCM for all 4,406 peaks with increased binding in DCM. As controls, we ran 200 iterations sampling 4,406 peaks from the consensus set of 38,883 peaks present in at least two adult samples. We calculated the mean and standard error of these data and plotted the 95% confidence interval for these controls. We also ran the corresponding analysis of the nearest transcription start site downregulated in DCM for all 3,101 peaks with less binding in DCM, and calculated a control set with 200 iterations randomly sampling 3,101 peaks from the same set of consensus peaks. We calculated the mean and standard error of these data and plotted the 95% confidence interval for these controls.
DCM and fetal peak comparison. As a control, we performed 200 iterations to choose random subsets of all 26,117 fetal peaks and intersected these with the differentially bound DCM vs Health peaks. We used these sets to establish the expected overlap between fetal-biased and DCM-biased peaks.
In vivo transgenic reporter assays. Enhancer candidate regions were cloned into an Hsp68-promoter-LacZ reporter vector39 using Gibson cloning 47 (New England Biolabs [NEB]). Transgenic mouse embryos were generated by pronuclear injection, and F0 embryos were collected at embryonic day 11.5 and stained for LacZ activity as previously described 25, 39 . Only patterns that were observed in at least three different embryos resulting from independent transgenic integration events of the same construct were considered reproducible. The procedures for generating transgenic and engineered mice were reviewed and approved by the Lawrence Berkeley National Laboratory (LBNL) Animal Welfare and Research Committee. 
